High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases
المؤلفون المشاركون
Fosko, Scott W.
Fesler, Mark J.
Armbrecht, Eric S.
Richart, John M.
Chu, Melinda B.
Hsueh, Eddy
المصدر
Chemotherapy Research and Practice
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-05-13
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
A retrospective review was performed on patients with stable melanoma brain metastases treated with HD IL-2 therapy (720,000 IU/kg per dose intravenously; 14 doses, 2 cycles per course, maximum 2 courses) from January 1999 to June 2011 at Saint Louis University.
There were 5 men and 3 women; median age was 52.2 years (26.8–61.1 years).
One patient started treatment with lung lesions only (after resection of melanoma brain disease) and experienced partial response.
Seven patients had brain metastases at treatment initiation.
Median overall survival (mOS) for entire cohort (n=8) was 8.7 months (2.1 to 19.0 months).
All patients with brain metastases at first dose (n=7) showed progressive disease; mOS was 6.7 months (range 2.1–18.2 months) for this group.
Patients received radiosurgery and whole brain radiation before and after HD IL-2 therapy.
One patient had symptoms suggestive of neurotoxicity.
A history of alcohol abuse was revealed during admission.
The patient's symptoms improved with initiation of an alcohol withdrawal protocol.
In this analysis, patients with melanoma brain metastases received HD IL-2 without treatment-related mortality.
We think that HD IL-2 should be considered as a treatment option in patients with melanoma brain metastases who are otherwise eligible for therapy.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Chu, Melinda B.& Fesler, Mark J.& Armbrecht, Eric S.& Fosko, Scott W.& Hsueh, Eddy& Richart, John M.. 2013. High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases. Chemotherapy Research and Practice،Vol. 2013, no. 2013, pp.1-7.
https://search.emarefa.net/detail/BIM-493797
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Chu, Melinda B.…[et al.]. High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases. Chemotherapy Research and Practice No. 2013 (2013), pp.1-7.
https://search.emarefa.net/detail/BIM-493797
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Chu, Melinda B.& Fesler, Mark J.& Armbrecht, Eric S.& Fosko, Scott W.& Hsueh, Eddy& Richart, John M.. High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases. Chemotherapy Research and Practice. 2013. Vol. 2013, no. 2013, pp.1-7.
https://search.emarefa.net/detail/BIM-493797
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-493797
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر